Lifastuzumab vedotin

Lifastuzumab vedotin
Monoclonal antibody
Type ?
Source Humanized (from mouse)
Target phosphate-sodium cotransporter
Clinical data
Synonyms DNIB0600A
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6504H10028N1744O2018S46
Molar mass 151.7 kg/mol

Lifastuzumab vedotin (DNIB0600A) (INN[1]) is a monoclonal antibody designed for the treatment of cancer.[2]

This drug was developed by Genentech/Roche.

References

  1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.